[Treatment of cognitive deficits in schizophrenia. Part 2: Pharmacological strategies].
Cognitive deficits in schizophrenia are a clinically relevant symptom dimension and one of the best predictors for functional outcome. Pharmacological treatment of cognitive deficits in schizophrenia is still a challenge. The objective of this article is to present a detailed review of the literature on strategies for the pharmacological treatment of cognitive deficits. It is not clear whether first-generation antipsychotics have a genuine positive influence on cognition. There is only sparse evidence for the positive effect of second-generation antipsychotics on cognitive processes. Furthermore it is not evident that second-generation antipsychotics are more beneficial than first-generation antipsychotics in the treatment of cognitive deficits. The add-on use of substances which directly influence cognitive processes, so-called cognition-enhancing drugs is more promising.
Roesch-Ely
D
D
Klinik für allgemeine Psychiatrie, Zentrum für Psychosoziale Medizin, Universitätsklinikum Heidelberg, Voss-Strasse 4, 69115, Heidelberg, Deutschland. daniela_roesch@med.uni-heidelberg.de
Pfueller
U
U
Mundt
C
C
Müller
U
U
Weisbrod
M
M
D000928:Antidepressive Agents / Q000008:administration & dosage*; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D018697:Nootropic Agents / Q000008:administration & dosage*; D012559:Schizophrenia / Q000188:drug therapy* / Q000628:therapy*
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D018697:Nootropic Agents